Nanomedicines for the treatment of autoimmune inflammation: engineering design, mechanisms and diseases
June 5-9, 2018
The complexity of autoimmune diseases is a barrier to the design of strategies that can blunt autoimmunity without impairing general immunity. We have shown that systemic delivery of nanoparticles (NPs) coated with autoimmune disease-relevant peptide-major-histocompatibility-complex (pMHC) molecules triggers the formation and profound expansion of antigen-specific T-regulatory T-cells in different mouse models, including mice humanized with lymphocytes from patients, leading to resolution of a broad range of established autoimmune phenomena. I will highlight the engineering principles impacting biological activity, will illustrate how these nanomedicines interact with cognate T-cells and will describe the pharmacokinetic behavior and toxicological profile of this novel class of drugs, potentially useful for treating a broad spectrum of autoimmune conditions in a disease-specific manner.
Pere Santamaria, "Nanomedicines for the treatment of autoimmune inflammation: engineering design, mechanisms and diseases" in "Nanotechnology in Medicine II: Bridging Translational in vitro and in vivo Interfaces", Millicent Sullivan, PhD, University of Delaware, USA Josué Sznitman, Dr. Sc., Technion-Israel Institute of Technology, Israel Lola Eniola-Adefeso, PhD, University of Michigan, USA Srivatsan Kidambi, PhD, University of Nebraska - Lincoln, USA Eds, ECI Symposium Series, (2018). http://dc.engconfintl.org/nanotech_med_ii/38